Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Recursion Pharmaceuticals (NASDAQ:RXRX) from a strong sell rating to a sell rating in a report issued on Saturday,Wall Street Zen reports.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Finally, Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, August 17th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $8.06.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $3.40 on Friday. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.82 billion, a P/E ratio of -3.27 and a beta of 1.03. Recursion Pharmaceuticals has a fifty-two week low of $2.77 and a fifty-two week high of $7.18. The firm’s 50 day moving average is $3.32 and its two-hundred day moving average is $3.34.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter last year, the business earned ($0.41) EPS. Analysts expect that Recursion Pharmaceuticals will post -0.92 EPS for the current year.

Insider Activity

In other news, CEO Najat Khan sold 23,588 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This trade represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $3.25, for a total transaction of $97,500.00. Following the transaction, the director directly owned 6,188,287 shares of the company’s stock, valued at approximately $20,111,932.75. This represents a 0.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 101,937 shares of company stock valued at $368,474 over the last 90 days. Insiders own 6.65% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently bought and sold shares of RXRX. Brighton Jones LLC raised its stake in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after buying an additional 6,699 shares in the last quarter. Royal Bank of Canada lifted its holdings in Recursion Pharmaceuticals by 627.6% during the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after buying an additional 232,038 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Recursion Pharmaceuticals by 7.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock worth $953,000 after acquiring an additional 12,372 shares in the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $77,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.